Skip to content
Accessibility help
Search NICE…
Skip to content
Menu
Sign in
Guidance
Standards and indicators
Life sciences
British National Formulary (BNF)
British National Formulary for Children (BNFC)
Clinical Knowledge Summaries (CKS)
About
Home
NICE guidance
In development
Guidance, NICE advice and quality standards
In development
Skip to filters
Skip to results
Published
In consultation
In development
Awaiting development
Topic selection
Filter (2 active)
Skip to results
Filter by title or keyword
Filter
Expected publication date
Expected publication date
From date
To date
Apply date filters
Area of interest
Area of interest
COVID-19 (6)
Type
(
1 selected
)
Type
Guidance (323)
Guidance programme
(
1 selected
)
Guidance programme
Clinical guidelines (28)
Diagnostics guidance (10)
Health technology evaluations (14)
Highly specialised technologies guidance (9)
Interventional procedures guidance (12)
Medical technologies guidance (11)
NICE guidelines (31)
Public health guidelines (1)
Technology appraisal guidance (323)
Apply filters
Showing 51 to 75 of 323
Sort by
Title
Date
Apply sorting
Type: Guidance
Remove Type: Guidance filter
Guidance programme: Technology appraisal guidance
Remove Guidance programme: Technology appraisal guidance filter
Guidance, NICE advice and quality standards in development
Title
Type
Expected publication date
Burosumab for treating X-linked hypophosphataemia in adults [ID3822]
Technology appraisal guidance
7 August 2024
Cabotegravir for preventing HIV-1 in adults and young people [ID6255]
Technology appraisal guidance
13 November 2024
Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]
Technology appraisal guidance
24 May 2019
Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]
Technology appraisal guidance
TBC
Canakinumab for adjuvant treatment of resectable or resected stage 2A to 3B non-small-cell lung cancer [ID5114]
Technology appraisal guidance
TBC
Capivasertib with fulvestrant for treating hormone receptor-positive HER2-negative advanced breast cancer after endocrine treatment [ID6370]
Technology appraisal guidance
5 March 2025
Capivasertib with paclitaxel for untreated metastatic triple-negative breast cancer [ID6383]
Technology appraisal guidance
TBC
Cediranib with olaparib for treating recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after 3 therapies [ID1639]
Technology appraisal guidance
TBC
Cemiplimab with platinum-based chemotherapy for untreated advanced non-small-cell lung cancer [ID3949]
Technology appraisal guidance
30 April 2025
Ciltacabtagene autoleucel for treating relapsed and lenalidomide-refractory multiple myeloma after 1 to 3 therapies [ID4012]
Technology appraisal guidance
TBC
Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [1259]
Technology appraisal guidance
TBC
Cladribine for treating relapsing multiple sclerosis ID6263
Technology appraisal guidance
5 February 2025
Cobolimab with dostarlimab and docetaxel for treating advanced non-small-cell lung cancer after anti-PD-L1 treatment and chemotherapy [ID6398]
Technology appraisal guidance
TBC
Colon cancer (adjuvant) - irinotecan [ID379]
Technology appraisal guidance
TBC
Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826]
Technology appraisal guidance
TBC
Crizotinib for treating ROS1-positive advanced non-small-cell lung cancer (MA review of TA529) [ID6289]
Technology appraisal guidance
16 October 2024
Crovalimab for treating paroxysmal nocturnal haemoglobinuria [ID6140]
Technology appraisal guidance
30 October 2024
Danicopan as an add-on treatment to a C5 inhibitor for treating extravascular haemolysis in adults with paroxysmal nocturnal haemoglobinuria [ID5088]
Technology appraisal guidance
11 September 2024
Dapagliflozin for treating chronic kidney disease [ID6411]
Technology appraisal guidance
12 February 2025
Daprodustat for treating anaemia in people with chronic kidney disease [ID3987]
Technology appraisal guidance
TBC
Daratumumab with bortezomib, lenalidomide and dexamethasone for untreated multiple myeloma when high-dose chemotherapy with stem cell transplant is unsuitable [ID3843]
Technology appraisal guidance
TBC
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297
Technology appraisal guidance
28 July 2021
Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297
Technology appraisal guidance
TBC
Datopotamab deruxtecan for previously treated hormone receptor-positive HER2-negative unresectable or metastatic breast cancer [ID6348]
Technology appraisal guidance
TBC
Datopotamab deruxtecan for treating advanced non-small-cell lung cancer after platinum-based chemotherapy [ID6241]
Technology appraisal guidance
TBC
Previous page
1
2
Current page
3
4
5
…
13
Page
3
of
13
Next page
Results per page
10
25
50
All
Back to top